RXRX RECURSION PHARMACEUTICALS, INC.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: AI-native drug discovery platform integrating biology, chemistry, clinical development to accelerate novel medicine creation
• • New emphasis: Clinical validation of Recursion OS in 2025 with positive Phase 1b/2 data for REC-4881 in familial adenomatous polyposis (FAP)
• • Strategic shift: Pivot from traditional high-attrition “V-shaped” funnel to a ‘T-shaped’ model emphasizing early attrition and AI-driven success probability
• • Quantitative highlight: Over $500M partner payments received; 90% fewer compounds synthesized vs industry average; clinical pipeline trimmed to 5 clinical programs in 2025
• • Noteworthy fact: First whole-genome CRISPR knockout neuronal and microglial maps created with Roche/Genentech, resulting in $60M milestone payments in 2024-2025

Risk Factors

• • FDA regulatory approval risk for all drug candidates currently in discovery or clinical stages, no products approved or commercial revenue as of 2026
• • Geopolitical risk from potential U.S. and foreign regulatory reviews on foreign investments, possibly limiting strategic alliances with international partners
• • Supply chain vulnerability linked to disruptions impacting clinical trial enrollment, manufacturing capacity, and timing of research activities
• • Competitive risk from industry consolidation reducing potential collaborators and increasing competition in neuroscience and oncology drug discovery
• • Financial risk of $2.1 billion accumulated deficit as of 12/31/2025 with ongoing need to raise capital through equity offerings, risking shareholder dilution

Management Discussion & Analysis

• • Revenue $74.7M in 2025, up 27% YoY from $58.8M driven by Sanofi partnership; 2024 revenue rose 32% from $44.6M primarily from Roche partnership
• • Operating margin negative 868% (loss $648.1M on revenue $74.7M) worsening from 815% in 2024 (loss $479.0M on $58.8M revenue)
• • Best segment: Research & Development expenses $475.3M up 51.2% YoY, driven by platform costs, Tempus record purchases ($49.9M), and Exscientia acquisition ($102.4M)
• • Worst segment: General & Administrative flat at $176.6M in 2025, down 0.9% YoY, but still a substantial cost burden
• • Cash flow: Operating cash outflow $371.8M increased; Financing inflow $521.5M mainly from equity sales; Cash & equivalents $753.9M end 2025
• • Capital allocation: Raised $957.1M net proceeds from stock since 2023; no product revenue yet; no buybacks or dividends reported
• • Outlook: Management plans multiple clinical data readouts and FDA engagement in 2026; key risk includes need for future capital raises; full valuation allowance maintained on Canadian DTAs

What are the latest RXRX SEC filings in 2026?

RECURSION PHARMACEUTICALS, INC. (RXRX) has filed a 10-K annual report on February 25, 2026, a 10-Q quarterly report on May 6, 2026, an 8-K current report on August 5, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did RXRX file its most recent 10-K annual report?

RECURSION PHARMACEUTICALS, INC. (RXRX) filed its most recent 10-K annual report on February 25, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view RXRX 10-Q quarterly reports?

RECURSION PHARMACEUTICALS, INC. (RXRX)'s most recent 10-Q quarterly report was filed on May 6, 2026. SignalX displays every RXRX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has RXRX filed recently?

RECURSION PHARMACEUTICALS, INC. (RXRX)'s most recent 8-K was filed on August 5, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find RXRX insider trading activity (Form 4)?

SignalX aggregates every RXRX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does RXRX file with the SEC?

RECURSION PHARMACEUTICALS, INC. (RXRX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new RXRX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for RECURSION PHARMACEUTICALS, INC. (RXRX).

What is RXRX's SEC CIK number?

RECURSION PHARMACEUTICALS, INC. (RXRX)'s SEC CIK (Central Index Key) number is 1601830. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1601830 to look up all RXRX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find RXRX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from RECURSION PHARMACEUTICALS, INC. (RXRX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.